Drug profile

The FDA adverse-event record for Indoxacarb Topic Oily Solution

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Indoxacarb Topic Oily Solution. See the species affected, top reactions, and outcomes below.

21
adverse-event reports
19.0%
death-coded share
Cat
most-reported species
5
Lack of efficacy (flea) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
4
Deaths Reported
19.0%
Death Rate

Active Ingredients

Indoxacarb Topic Oily Solution

Administration Routes

Topical

Species Affected

Cat 12
Dog 9

Most Affected Breeds

Domestic Shorthair 8
Greyhound 1
Dog (other) 1
Retriever - Golden 1
Crossbred Canine/dog 1
Shepherd Dog - German 1
Chihuahua 1
Terrier - Scottish 1
Domestic Longhair 1
Domestic Mediumhair 1

Most Reported Reactions

Lack of efficacy (flea) 5
Seizure NOS 4
Death 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Overdose 3
Lack of efficacy (ectoparasite) - flea 3
Emesis (multiple) 2
Diarrhoea 2
Application site alopecia 2
Application site burn 2
Application site erythema 2
Application site hot spot 2

Outcome Breakdown

Ongoing
14 (66.7%)
Died
3 (14.3%)
Outcome Unknown
2 (9.5%)
Euthanized
1 (4.8%)
Recovered/Normal
1 (4.8%)

Indoxacarb Topic Oily Solution Adverse Event Insights

21 reports name Indoxacarb Topic Oily Solution; 4 recorded a death outcome (19.0% of reported events, not a population-level mortality rate). Active ingredient: Indoxacarb Topic Oily Solution. Administration route: Topical.

By species: Cat (12 reports), Dog (9 reports). By breed: Domestic Shorthair (8), Greyhound (1), Dog (other) (1).

Leading clinical signs: Lack of efficacy (flea) (5), Seizure NOS (4), Death (3), Lethargy (see also Central nervous system depression in 'Neurological') (3). Outcome, 21 coded reports: Ongoing leads at 66.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.